Market expansion Galenika has a long-standing regional footprint in Serbia with growth ambitions and a recent peptide-based platform launch in collaboration with EMS Brazil, presenting an opportunity to position our solutions for regional partnerships, distribution enhancements, and cross-border sales initiatives.

Innovation driver Recognition as an innovation leader and the launch of a peptide-based platform indicate a strong openness to collaborating on R&D, contract manufacturing, and co-development arrangements that can expand our product portfolio and shorten time-to-market for new therapies.

Strategic partnership Since becoming part of EMS in 2017, Galenika pursues high-quality products under a trusted global umbrella. This presents a pathway for joint ventures, licensing, and OEM opportunities leveraging EMS’s regional reach and Galenika’s manufacturing capabilities.

Health focus With a brand promise around health and consumer trust and ongoing consumer education initiatives, there is potential to offer digital health tools, patient support programs, and compliance-oriented services that align with Galenika’s consumer-facing strategy.

Scale and capability A mid-sized workforce (201-500) and a history of modernizing production facilities suggests capacity for incremental manufacturing contracts, private-label lines, and accelerated supply of specialty pharmaceuticals to new markets and partners.